Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
After radiolabelling with gallium-68, edotreotide binds somatostatin receptors with high affinity, mainly SSTR2 and to a lesser extent SSTR5, enabling PET localisation of somatostatin-receptor-expressing lesions.
Indications / reported uses
Diagnostic PET imaging of somatostatin-receptor overexpression in adults with confirmed or suspected well-differentiated gastro-enteropancreatic neuroendocrine tumours, for localisation of primary tumours and metastases; edotreotide kit requires radiolabelling before administration
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Edotreotide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Edotreotide Permitted Daily Exposure (PDE) report (the Edotreotide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Edotreotide Occupational Exposure Limit (OEL) report (the Edotreotide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.